Stem Cell Cartilage Regeneration via Intra-articular Debris Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis primarily focus on alleviating symptoms and do not effectively regenerate damaged cartilage, leading to progressive degeneration and disability, with existing therapies failing to halt the disease progression or restore joint function.
Innovation Solution
The method involves administering autologous or allogeneic mesenchymal stem cells, combined with agents like hyaluronidase, to the affected joint to regenerate cartilage and subchondral bone, using a biomatrix delivery system that includes collagen-based products, and optionally growth factors, to promote cartilage repair and integration with existing tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (NSAIDs, steroids, DMARDS) are used to manage osteoarthritis, then symptom relief and inflammation reduction are achieved, but cartilage regeneration does not occur and disease progression continues
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach from symptom management to regenerative biology. By introducing stem cell populations with specific properties (autologous or allogeneic mesenchymal stem cells) and controlling their differentiation through growth factors, the treatment transitions from passive symptom relief to active cartilage regeneration, thereby halting disease progression while producing functional cartilage tissue.
Solution Approach 2:
The patent uses growth factors as intermediary substances that mediate between the administered stem cells and the target cartilage tissue. These growth factors (such as TGF-β, BMPs, PDGF) act as signaling molecules that guide stem cell differentiation and promote cartilage formation, enabling the stem cells to regenerate cartilage rather than merely reducing inflammation.
2Productivity
If autologous tissue grafts are used for cartilage repair, then cartilage regeneration is achieved, but surgical complexity and donor site morbidity increase
Solution Approach 1:
The patent extracts the regenerative function from complex autologous tissue grafting procedures. Instead of harvesting and manipulating patient's own cartilage or bone grafts through complex surgical procedures, the treatment extracts stem cells from easily accessible sources (bone marrow, adipose tissue) and delivers them as a simplified cellular product, eliminating the need for complex graft surgery while maintaining regenerative capability.
Solution Approach 2:
The patent creates a functional copy of cartilage regeneration without requiring actual autologous tissue grafts. By using stem cells that can differentiate into cartilage-producing cells and delivering them with appropriate growth factors, the treatment produces cartilage regeneration as a biological copy rather than requiring physical grafting, thereby simplifying the surgical procedure.
3Productivity
If stem cell populations are administered to regenerate cartilage, then cartilage defects can be repaired, but the presence of intra-articular debris may interfere with regenerative activity
Solution Approach 1:
The patent applies preliminary action by administering agents to remove or reduce intra-articular debris before stem cell population administration. This preliminary cleaning step eliminates harmful factors (debris, inflammation) that would interfere with stem cell function, thereby creating an optimal environment for cartilage regeneration while maintaining the regenerative activity of the stem cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the regeneration of both shallow and full-thickness cartilage defects, broadening the treatment scope to include middle-aged patients, eliminating the need for autologous tissue grafts, and forming new cartilage that integrates with adjacent tissue, thereby stabilizing joints and potentially deferring or avoiding advanced surgical interventions.
Implementation Method 1
said agent capable of decreasing debris found in the articular space is hyaluronidase
Implementation Method 2
said agent capable of decreasing debris found in the articular space is a protease
Implementation Method 3
said protease is a matrix metalloprotease
Data Source
AI summary
Methods of enhancing efficacy of cartilage regenerative therapies through reducing particulate and/or cellular debris residing in the intra-articular space. In one embodiment the invention teaches administration of low-dose protease and/or matrix metalloprotease and/or hyaluronidase prior to administration of stem cells in order to clear tissue of debris capable of suppressing regenerative activity of stem cells. In one embodiment of the invention clinical grade hyaluronidase is administered intra-articular in a patient receiving bone marrow aspirate/mononuclear cell therapy.